文献速递外周动脉疾病

药物洗脱可吸收支架治疗膝下动脉病变的系统综述与荟萃分析

Systematic Review and Meta-Analysis of Drug-Eluting Resorbable Scaffolds for Infrapopliteal Arterial Disease.
PubMed 文献 · J Endovasc Ther · 2026-06-14

该系统综述与荟萃分析纳入7项研究共497例患者,评估药物洗脱可吸收支架(DRS)治疗膝下动脉病变的疗效与安全性。结果显示12个月一期通畅率88%、免于临床驱动靶血管血运重建率95%、肢体挽救率99%、30天全因死亡率免除率99%。作者认为DRS通畅率高、再干预率低,但需大规模随机对照试验进一步验证。

要点

  • DRS治疗膝下动脉病变12个月一期通畅率达88%,免于CD-TLR达95%。
  • 12个月肢体挽救率99%,30天全因死亡免除率99%,安全性良好。
  • 证据以观察性研究为主,DRS优于单纯PTA尚不能确立,需RCT验证。

核心结论

  • 在以便观察性研究为主的系统综述中,药物洗脱可吸收支架与膝下动脉病变的高通畅率和低再干预率相关。
  • 仍需大规模随机对照试验直接比较DRS与PTA并进一步研究长期耐久性。

研究设计与样本

  • 纳入7项研究,包括1项随机对照试验、3项前瞻性研究和3项回顾性研究,共497例患者。

主要发现

  • DRS治疗膝下动脉病变12个月一期通畅率为88%(95%CI=0.81-0.93)。
  • 12个月免于临床驱动靶血管血运重建(CD-TLR)率为95%(95%CI=0.93-0.97)。
  • 12个月肢体挽救率为99%(95%CI=0.97-1.00),30天全因死亡免除率为99%(95%CI=0.97-1.00)。

临床怎么用

  • 现有数据支持DRS作为特定慢性肢体威胁性缺血患者的辅助治疗选择。
  • 由于随机试验有限且缺乏长期随访,DRS优于单纯球囊扩张的结论尚不能确立。

局限性

  • 纳入研究以观察性研究为主,随机对照试验仅1项,证据等级受限。
  • 缺乏长期随访数据,DRS与PTA的直接比较证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Drug-eluting resorbable scaffold (DRS) has emerged as a promising adjunctive treatment to traditional percutaneous transluminal angioplasty (PTA) for infrapopliteal arterial disease. This systematic review aims to evaluate the clinical efficacy and safety of DRS in this application. METHODS: PubMed, ScienceDirect, and Embase databases were systematically searched as of November 2025. Studies concerning infrapopliteal arterial revascularization using DRS were included. The primary endpoints were 12-month primary patency rate and freedom from clinically driven target vessel revascularization (CD-TLR). Secondary endpoints included 12-month limb salvage rate and 30-day all-cause mortality. RESULTS: Seven studies, comprising 1 randomized controlled trial, 3 prospective, and 3 retrospective studies, including 497 patients were included in the analysis. Treatment of infrapopliteal arterial lesion with DRS yielded a 12-month primary patency of 88% (95% CI = 0.81-0.93) and a 12-month freedom from CD-TLR of 95% (95% CI = 0.93-0.97). The 12-month limb salvage rate was 99% (95% CI = 0.97-1.00), and freedom from 30-day all-cause mortality rate was 99% (95% CI = 0.97-1.00). CONCLUSION: Drug-eluting resorbable scaffold was associated with high patency and low reintervention rates in this systematic review of predominantly observational studies. Nevertheless, additional large-scale randomized controlled trials are warranted for direct comparison between DRS and PTA and further investigation to establish long-term durability.Clinical ImpactBy summarizing recent data from interventional and observational studies, this systematic review demonstrated favourable efficacy and safety of drug-eluting resorbable scaffolds (DRS) in the treatment of infrapopliteal arterial disease. While superiority of DRS over conventional balloon angioplasty alone could not be established due to limited randomized trials and lack of long-term follow-up. The available data support use of DRS as an adjunctive option in selected patients with chronic limb-threatening ischemia.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Lau JTY, Li HL, Tong KS, et al. Systematic Review and Meta-Analysis of Drug-Eluting Resorbable Scaffolds for Infrapopliteal Arterial Disease. J Endovasc Ther. 2026. PMID: 42289871. doi:10.1177/15266028261453275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。